Olympus Enters Strategic Partnership for Development of Endoluminal Gastrointestinal robotics
- Olympus will take a significant equity stake with Swan EndoSurgical, with a combined investment of at least $65,000,000. Swan EndoSurgical will develop an innovative endoluminal robot system for less invasive therapies.
- If pre-agreed goals are met and the program is completed, the total combined funding may reach $458 million.
TOKYO – July 25, 2025 (JCN Newswire –Olympus Corporation, a global MedTech firm committed to making lives healthier, safer and more fulfilling for people, announced today the conclusion of an accord with Revival Healthcare Capital to drive advancements within endoluminal robots. Olympus will co-found Swan EndoSurgical with Revival, a company dedicated to the development of a novel robotic system that is designed to revolutionize GI patient care in future. Swan EndoSurgical logo
Endoscopy, which involves inserting a flexible camera in an existing body orifice, has been used to diagnose conditions like GI tract carcinoma early and accurately. In recent years, gastroenterologists have started performing endoscopic therapeutic procedures such as cancer removal by inserting instruments into the endoscope. Manual endoscopes, and their instruments, have limitations which make advanced procedures in the lumens of the GI tract difficult and not widely available.
With its ability to maneuver easily within the GI track and deploy flexible arms it allows more patients to benefit. This could potentially avoid invasive surgery. This innovation allows early, safe and effective treatment of lesions in the GI tract compared to current therapeutic options. The technology can also be used in other areas of disease. Swan EndoSurgical, headquartered in the United States has assembled a team of highly-experienced industry professionals to drive the technical, clinical, as well as commercial development of the robot platform. Swan EndoSurgical
About Swan EndoSurgical. Swan EndoSurgical, Inc., a start-up founded by Revival Healthcare Capital, Olympus, and focused on the development endoluminal robotics, aims to provide effective treatment for lesions or tumors of the GI tract compared to current therapeutic options. For additional information, visit the Company’s website at www.swanendosurgical.com or contact info@swansurg.com. Revival Healthcare Capital –
Revival Healthcare Capital focuses on the MedTech industry. Revival is a specialist in external innovation partnerships, as well as other opportunities, where its team of experienced investors and operators believes that it can provide leadership, resources and deep sector insight – beyond capital – to support companies’ growth strategy. Revival has a website at www.rvlhc.com (19459042) or you can contact info@rvlhc.com for more information.
Olympus
We are committed to our Purpose at Olympus of making peoples’ lives healthier, safer and more fulfilling. As a global medical tech company, we work with healthcare professionals to develop innovative solutions and services to improve patient outcomes. Olympus’ goal for more than 100 years has been to contribute to society through the production of products that deliver optimal outcomes for customers around the globe. For more information, visit https://www.olympus-global.com/and follow our global X account: @Olympus_Corp.
Media contact:
Mail: Global-Public_Relations@olympus.com
Olympus Corp [TYO: 7733] [ADR: OLYMY] [STU: OLY1] [FRA: OLYS] https://www.olympus-global.com
Source: Olympus
Sectors: Healthcare & Pharm, Engineering, Funds & Equities, Automation [IoT], MedTech
Copyright (c)2025 JCN Newswire. All rights reserved. All rights reserved.
